Breaking Finance News

RBC Capital announced Incyte (NASDAQ:INCY), boosting its stock price target to $113.00 today

In a report released on 10/12/2016 RBC Capital increased the stock price target of Incyte (NASDAQ:INCY) from $106.00 to $113.00 reporting a possible upside of 0.23%.

Previously on 10/4/2016, Zacks Investment Research released a statement about Incyte (NASDAQ:INCY) increased the target price from $0.00 to $107.00. At the time, this indicated a possible upside of 0.13%.

Just yesterday Incyte (NASDAQ:INCY) traded -4.00% lower at $92.11. Incyte’s 50-day moving average is $86.25 and its 200-day moving average is $81.33. The last stock price is up 13.25% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,938,127 shares of INCY traded hands, up from an average trading volume of 1,276,920

Recent Performance Chart


Incyte has 52 week low of $55.00 and a 52 week high of $124.98 with a PE ratio of 250.30 and has a market capitalization of $0.

In addition to RBC Capital reporting its stock price target, a total of 14 analysts have released a report on Incyte. The 12-month price target is $91.36 with seven analysts rating the company a strong buy, eight analysts rating the company a buy, one broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Incyte (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.